多巴胺能神经传递与遗传变异在术后慢性疼痛中的作用
术后慢性疼痛(CPSP)影响10-50%的手术患者,现有治疗策略不理想。本文为叙述性综述,聚焦多巴胺(DA)神经传递作为CPSP治疗潜在靶点,综述了DA神经传递相关遗传变异(COMT、GCH1、DRD2)与疼痛敏感性、CPSP发生及镇痛需求的关系。证据提示DA具有调节作用,针对DA神经传递的药物治疗在CPSP预防(D1样受体)和治疗(D2样受体及DA再摄取抑制剂)方面有潜力,有必要开发纳入遗传风险因素的预测模型。
要点
- CPSP影响10-50%手术患者,现有治疗不理想。
- COMT、GCH1、DRD2基因与疼痛敏感性、CPSP及镇痛需求相关。
- DA是疼痛治疗的良好药理靶点,D1样受体或用于预防,D2样受体及DA再摄取抑制剂或用于治疗。
核心结论
- 多巴胺能神经传递在CPSP中起调节作用,是预防和治疗的潜在药理靶点。
- 需要开发纳入遗传风险因素的预测模型以更好识别高危患者。
研究设计与样本
- 叙述性综述,聚焦DA神经传递作为CPSP治疗潜在靶点,综述DA神经传递遗传变异与CPSP易感性的现有知识。
主要发现
- CPSP影响10-50%的手术患者,当前治疗策略不理想。
- COMT、GCH1和DRD2三个DA神经传递相关基因与疼痛敏感性变异、CPSP发生及镇痛需求相关。
- 关联效应方向有时因结果矛盾而不确定,但充分证据提示DA的调节作用。
关键数值与推荐
- CPSP影响10-50%的手术患者。
- COMT、GCH1和DRD2与疼痛敏感性、CPSP发生及镇痛需求相关。
- 针对DA神经传递的药物治疗在预防(D1样受体)和治疗(D2样受体及DA再摄取抑制剂)CPSP方面有潜力。
临床怎么用
- 关注COMT、GCH1、DRD2等DA相关基因变异以评估CPSP风险。
- D1样受体可能用于CPSP预防,D2样受体及DA再摄取抑制剂可能用于治疗。
- 推动纳入遗传风险因素的CPSP预测模型开发。
局限性
- 部分关联效应方向因结果矛盾而不确定。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Chronic post-surgical pain (CPSP) is a debilitating condition affecting 10-50% of surgical patients. The current treatment strategy for CPSP is not optimal, and the identification of genetic variation in surgical patients might help to improve prediction and treatment of CPSP. The neurotransmitter dopamine (DA) has been associated with several chronic pain disorders. This narrative review focuses on DA neurotransmission as a potential target in the treatment of CPSP. The current knowledge on genetic variation within DA neurotransmission and its role in CPSP susceptibility are reviewed. Three genes involved in DA neurotransmission (COMT, GCH1, and DRD2) have been associated with variability in pain sensitivity, development of CPSP, and analgesic requirement. The direction of the effect of the association is sometimes inconclusive because of contradictory results, but ample evidence suggests a modulatory role of DA. Because of this modulatory role, DA is an excellent pharmacological target in the treatment of pain. Pharmacotherapy focused on DA neurotransmission has potential in both prevention (via D1-like receptors) and treatment (via D2-like receptors and DA reuptake inhibitors) of CPSP. The development of prediction models including genetic risk factors is necessary to better identify patients at risk.
引用
- van Reij RRI, Joosten EAJ, van den Hoogen NJ, et al. Dopaminergic neurotransmission and genetic variation in chronification of post-surgical pain. Br J Anaesth. 2019. PMID: 31558312. doi:10.1016/j.bja.2019.07.028
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。